No Data
Jinyu Bio-technology's (SHSE:600201) Soft Earnings Are Actually Better Than They Appear
jinyu bio-technology (600201.SH): No share repurchase for now
Gelonghui November 4th | Jinyu bio-technology (600201.SH) announced that as of October 31, 2024, the company has not repurchased shares yet. The company will implement the repurchase plan at an opportune time according to market conditions.
Estimating The Fair Value Of Jinyu Bio-technology Co., Ltd. (SHSE:600201)
Jinyu Bio-technology Obtains Drug Registration Certificate for Bovine Brucellosis Vaccine
Jinyu bio-technology (600201.SH): Subsidiary obtains new veterinary drug registration certificate
Jinyu Bio-Technology (600201.SH) announced on October 31st that, in accordance with the national "Veterinary Drug Administration Regulations" and "Veterinary Drug Registration Measures", after review by the Ministry of Agriculture and Rural Affairs, the fully-owned subsidiary of Jinyu Bio-Technology, Jinyu Baoling Biopharmaceutical Co., Ltd. (referred to as "Jinyu Baoling"), was approved to participate in the research and development of the Brucellosis live vaccine (S19 strain), which is a new veterinary drug. The company was issued the "New Veterinary Drug Registration Certificate". Brucellosis is a zoonotic infectious disease caused by Brucella. In order to effectively prevent and control bovine brucellosis, the company collaborated with the United States Department of Agriculture's Animal and Plant Health Inspection Service and the National Veterinary Bureau.
Biotech Shares: Jinyu Biotechnology Co., Ltd. Report for the Third Quarter of 2024
Positive Earnings Growth Hasn't Been Enough to Get Jinyu Bio-technology (SHSE:600201) Shareholders a Favorable Return Over the Last Three YearsNo Data
No Data
